Add These Presentations to Your AAN Meeting Itinerary

This year’s American Academy of Neurology Annual Meeting is approaching fast. If you’re going to Boston for the late-April meeting, make room in your itinerary for the following selected key presentations by Cleveland Clinic experts.

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

If you can’t make it to the conference, check back here on Consult QD or on Cleveland Clinic’s social media channels for medical professionals (@CleClinicMD or Facebook.com/CMEClevelandClinic) for reports on most presentations below soon after they take place.

Parkinson’s Disease Update: Part I

First half of a two-hour CME event on Parkinson’s disease

Presented by Hubert Fernandez, MD, Director, Cleveland Clinic Center for Neurological Restoration

Sat., April 22, 8-9 a.m.

CSF Total Tau in Alzheimer’s Disease

Poster P1.093: “Elevated cerebrospinal fluid total Tau level reflects predominant cortical atrophy in Alzheimer’s disease”

Presented by Jagan Pillai, MD, PhD, Cleveland Clinic Lou Ruvo Center for Brain Health

Sun., April 23, 8:30 a.m.-5:30 p.m.

Stem Cells in Neurological Diseases

“The Devilish Details, Challenges, and Uncertainties,” a talk in the “Section Topic Controversies” session on stem cells for treatment of neurological diseases

Presented by Jeffrey Cohen, MD, Director, Cleveland Clinic Mellen Center for MS Treatment and Research

Tue., April 25, 4:00-4:30 p.m.

RADIANCE 2-Year Blinded Extension Results

Platform presentation S24.008: “Efficacy and safety of ozanimod: Results from the 2-year blinded extension of the RADIANCE phase 2 trial in relapsing multiple sclerosis”

Presented by Jeffrey Cohen, MD, Director, Cleveland Clinic Mellen Center for MS Treatment and Research

Tue., April 25, 4:54-5:06 p.m.

AIM-TD Trial of Deutetrabenazine for Tardive Dyskinesia

Platform presentation S56.004: “Addressing involuntary movements in tardive dyskinesia (AIM-TD): Improvements in Clinical Global Impression of Change with deutetrabenazine treatment in moderate to severe tardive dyskinesia”

Presented by Hubert Fernandez, MD, Director, Cleveland Clinic Center for Neurological Restoration

Fri., April 28, 4:06-4:18 p.m.